The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IASLC TTLC 2022 | Assessing immunotherapy in various subtypes of lung cancer
KRAS is the most frequently observed driver mutation in patients with lung who receive from immunotherapy, with the G12C mutation being the most common subset in those patients. Jia Luo, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the efficacy of immunotherapy in patients with other KRAS mutations. Patients with G12D mutations, which are more prevalent in non-smokers, are found to benefit less from immunotherapy. Dr Luo additionally highlights the need for more clinical trials identifying which subsets of patients with other mutations such as STK11 mutations will benefit from immunotherapy the most. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).
